Cargando…

Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations

Dihydroergotamine (DHE) is an ergot alkaloid derivative of substances produced by rye fungus. Ergotamine was first used in the field of gynecology and obstetrics, then used for migraine treatment a few years later. DHE was developed as a derivative of ergotamine. DHE, when compared to ergotamine, de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafqat, Rafia, Flores-Montanez, Yadira, Delbono, Victoria, Nahas, Stephanie J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200221/ https://www.ncbi.nlm.nih.gov/pubmed/32431533 http://dx.doi.org/10.2147/JPR.S203650

Ejemplares similares

Dihydroergotamine (DHE) – Then and Now: A Narrative Review
por: Silberstein, Stephen D., et al.
Publicado: (2019)

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
por: Albrecht, Detlef, et al.
Publicado: (2020)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
por: Bérard, Anick, et al.
Publicado: (2021)

Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
por: Cooper, Wade, et al.
Publicado: (2022)

Does DHE imaging shed insight into the inaccuracy of EKGs?
por: Nadour, Wadih, et al.
Publicado: (2009)

Saclay : Applications des ions d'He en radiothérapie
Publicado: (1977)

EHMTI-0125. Studying the permeability of the blood-brain barrier during migraine attacks using [11C]-dihydroergotamine
por: Schankin, C, et al.
Publicado: (2014)

Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for (11) C-dihydroergotamine during glyceryl trinitrate-induced migraine
por: Schankin, Christoph J., et al.
Publicado: (2016)

Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries
por: Labruijere, S, et al.
Publicado: (2013)

Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache
por: Robbins, Nathaniel M., et al.
Publicado: (2016)

Dihydroergotamine Complicating Reversible Cerebral Vasoconstriction Syndrome in Status Migrainosus
por: Mullaguri, Naresh, et al.
Publicado: (2018)

Pectus updates and special considerations in Marfan syndrome
por: Fraser, Stephanie, et al.
Publicado: (2018)

Digital Health Europe (DHE) Twinning on severe asthma—kick-off meeting report
por: Bousquet, Jean, et al.
Publicado: (2021)

Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat
por: Tfelt-Hansen, Peer, et al.
Publicado: (2007)

Observations of the “carry–over effect” following successful termination of chronic migraine in the adolescent with short–term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study
por: Charles, J. A., et al.
Publicado: (2005)

Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
por: Kori, S, et al.
Publicado: (2013)

Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine
por: Mojica, Jeffrey J., et al.
Publicado: (2021)

Disheveled Hair and Ear (Dhe), a Spontaneous Mouse Lmna Mutation Modeling Human Laminopathies
por: Odgren, Paul R., et al.
Publicado: (2010)

Infection susceptibility and immune senescence with advancing age replicated in accelerated aging Lmna (Dhe) mice
por: Xin, Lijun, et al.
Publicado: (2015)

The decisive role of cardiovascular MRI delayed hyperenhancement (DHE) pattern for risk stratification for dilated cardiomyopathy
por: Venero, Jose V, et al.
Publicado: (2009)

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
por: Stagnoli, Soledad, et al.
Publicado: (2023)

Neuropeptide release from slices of rat and guinea pig trigeminal ganglia: modulation by dihydroergotamine and sumatriptan
por: Tognetto, Michele, et al.
Publicado: (2000)

Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor
por: Zheng, Ke-Xin, et al.
Publicado: (2023)

A Consideration of the Casting Process, with Special Reference to Refractory Materials
por: Ward, Marcus L.
Publicado: (1909)

Mitotic Defects Lead to Pervasive Aneuploidy and Accompany Loss of RB1 Activity in Mouse Lmna(Dhe) Dermal Fibroblasts
por: Pratt, C. Herbert, et al.
Publicado: (2011)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

536 Effect of Diet Supplementation with Epa-Dhe on Pulmonary Function Tests and Metacholine Bronchial Challenge Test in Obese Mexican Children
por: Pineda-Bahena, Luisa Guadalupe, et al.
Publicado: (2012)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

Multiorgan Development of Oxidative and Nitrosative Stress in LPS-Induced Endotoxemia in C57Bl/6 Mice: DHE-Based In Vivo Approach
por: Proniewski, Bartosz, et al.
Publicado: (2019)

Penile Prosthesis Implantation in Refractory Ischaemic Priapism: Patient Selection and Special Considerations
por: Capece, Marco, et al.
Publicado: (2022)

Chronic migraine: treatability, refractoriness, pseudo-refractoriness
por: Barbanti, Piero, et al.
Publicado: (2015)

Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine
por: Noveck, Robert J, et al.
Publicado: (2013)

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
por: González-Hernández, Abimael, et al.
Publicado: (2018)

The role of α(1)- and α(2)-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats
por: Rivera-Mancilla, Eduardo, et al.
Publicado: (2017)

Brachial Artery Vasospasm From Sequential Use of Intravenous Promethazine and Dihydroergotamine for Treatment of Status Migrainosus: A Case Report
por: Johns, Christopher, et al.
Publicado: (2023)

A Clinical Consideration of Migraine
por: Litchy, John A.
Publicado: (1917)

Migraine and quality of life: psychological considerations
por: Andrasik, Frank
Publicado: (2001)

Genetics of migraine and pharmacogenomics: some considerations
por: Piane, Maria, et al.
Publicado: (2007)

Management considerations in the treatment of migraine in adolescents
por: Matarese, Christine A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8vfv63jql97nh4cp5mi4njhhpt